Hong Kong-based pharmaceutical company Aptorum Group Limited is seeking to raise up to US$30 million in an initial public offering of its class A ordinary shares in the U.S., according to a statement released by the company yesterday.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?